Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Non-Comparative, Randomised Controlled Trial of Stereotactic Ablative Body Radiotherapy and Immunotherapy Versus Immunotherapy Alone in Patients With Treatment Naïve Oligometastatic Extracranial Melanoma

NCT06767306 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT06767306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06767306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Non-Comparative, Randomised Controlled Trial of Stereotactic Ablative Body Radiotherapy and Immunotherapy Versus Immunotherapy Alone in Patients With Treatment Naïve Oligometastatic Extracranial Melanoma
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2025
Completion date
April 1, 2033
Enrollment
129 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma metastatic